eligibility_summary
Inclusion: ECOG 0–1, ≥40 kg, ≥12‑week life expectancy, HLA‑A02+ and MAGE‑A4+ tumor, advanced/metastatic solid tumor refractory/relapsed, measurable disease (RECIST 1.1), adequate organ function, toxicities ≤Grade 2, tumor tissue required. Exclusion: pregnancy/breastfeeding/planned conception, cardiopulmonary/liver disease, poorly controlled T2DM, HBV/HCV, HIV, alpha‑gal allergy, active CNS mets, symptomatic effusions/recent drainage, autoimmune/immune deficiency, immunosuppression, prior allogeneic/organ transplant.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: RO7617991 (IV), a TCR-based bispecific T‑cell engager biologic, and tocilizumab (IV), an anti–IL‑6 receptor monoclonal antibody given as needed for cytokine release syndrome. Mechanisms of action: RO7617991 binds the MAGE‑A4 peptide presented by HLA‑A02 on tumor cells and CD3 on T cells, redirecting and activating polyclonal cytotoxic T cells to induce tumor cell killing. Tocilizumab blocks IL‑6 signaling to mitigate CRS. Cells/pathways targeted: MAGE‑A4–positive tumor cells via the MAGE‑A4/HLA‑A02 complex, T cells via CD3/TCR signaling with downstream activation and cytotoxicity, inflammatory cytokine pathway (IL‑6) during immune activation.